Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2019

01-12-2019 | Metastasis | Research Article

Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases

Authors: C. Pedrazzani, G. Turri, G. Mantovani, C. Conti, R. Ziello, S. Conci, T. Campagnaro, A. Ruzzenente, A. Guglielmi

Published in: Clinical and Translational Oncology | Issue 12/2019

Login to get access

Abstract

Purpose

The purpose of this study was to evaluate the prognostic role of thrombocytosis in patients with synchronous colorectal liver metastases (CRLM).

Methods

Retrospective analysis of patients who underwent surgery for colorectal cancer with synchronous CRLM at the Division of General and Hepatobiliary Surgery, University of Verona Hospital Trust between 2005 and 2016.

Results

One hundred and ninety-six patients met the inclusion criteria. High platelet count (H-PC) was found in 32%, and it was associated with a higher rate of palliative surgery (p < 0.001), extra-hepatic metastases (p < 0.001), bilobar liver disease (p = 0.007), presence of more than three metastases (p = 0.005), biggest metastasis larger than 5 cm (p < 0.001), and CEA level higher than 200 ng/mL (p = 0.035). H-PC was significantly associated with poorer 5-year overall survival (14.3% vs. 34.3%; p = 0.001). At the multivariate analysis on R0-1 cases, platelet count resulted the only independent predictor of survival (HR 2.07, p = 0.036).

Conclusion

H-PC correlates with the main negative clinical–pathological factors in patients with synchronous CRLM, as well as with overall survival. Moreover, it was the only independent prognostic factor in those who underwent curative surgery.
Literature
1.
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.CrossRef
2.
3.
Sandström P, Røsok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis. Ann Surg. 2017;267:1.
4.
Torzilli G, Adam R, Viganò L, Imai K, Goransky J, Fontana A, et al. Surgery of colorectal liver metastases: pushing the limits. Liver Cancer. 2016;6:80–9.CrossRef
5.
Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, et al. Resection of colorectal liver metastases after second-line chemotherapy: Is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017;78:7–15.CrossRef
6.
Akgül Ö, Çetinkaya E, Ersöz Ş, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol 2014;20:6113–22.CrossRef
7.
Mattar RE, Al-Alem F, Simoneau E, Hassanain M. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol. 2016;22:567–81.CrossRef
8.
9.
Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.CrossRef
10.
Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–62.CrossRef
11.
12.
Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surci N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017;7:1–10.CrossRef
13.
Kozak MM, von Eyben R, Pai JS, Anderson EM, Welton ML, Shelton AA, et al. The prognostic significance of pretreatment hematologic parameters in patients undergoing resection for colorectal cancer. Am J Clin Oncol. 2017;40:405–12.CrossRef
14.
Dell’Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018;29:924–30.CrossRef
15.
Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A. AJCC cancer staging manual, 7th ed. 2010.
16.
Pedrazzani C, Lauka L, Sforza S, Ruzzenente A, Nifosì F, Delaini GG, et al. Management of nodal disease from colon cancer in the laparoscopic era. Int J Colorectal Dis. 2015;30:303–14.CrossRef
17.
Pang YY, Strasberg SM. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333–9.CrossRef
18.
Agha RA, Borrelli MR, Vella-Baldacchino M, Thavayogan R, Orgill DP, Pagano D, et al. The STROCSS statement: strengthening the reporting of cohort studies in surgery. Int J Surg. 2017;46:198–202.CrossRef
19.
Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175:859–63.CrossRef
20.
Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.CrossRef
21.
Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198:737–41.CrossRef
22.
Guo T, Krzystanek M, Szallasi Z, Szallasi A. Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Research. 2014;3:180.CrossRef
23.
Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, Martinez-Gómez H, Maffuz A, Rojas-Garcia P, et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res. 2012;43:305–11.CrossRef
24.
Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013;44:293–304.CrossRef
25.
Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968;61:46–52.CrossRef
26.
Pearlstein E, Ambrogio C, Karpatkin S. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. Cancer Res. 1984;44:3884–7.PubMed
27.
Kawai K, Watanabe T. Colorectal cancer and hypercoagulability. Surg Today. 2014;44:797–803.CrossRef
28.
Poggi A, Stella M, Donati MB. The importance of blood cell-vessel wall interactions in tumour metastasis. Baillieres Clin Haematol. 1993;6:731–52.CrossRef
29.
Placke T, Kopp H-G, Salih HR. The wolf in sheep’s clothing: platelet-derived “pseudo self” impairs cancer cell “missing self” recognition by NK cells. Oncoimmunology. 2012;1:557–9.CrossRef
30.
Seretis C, Youssef H, Chapman M. Hypercoagulation in colorectal cancer: What can platelet indices tell us? Platelets. 2015;26:114–8.CrossRef
31.
Pedrazzani C, Mantovani G, Salvagno GL, Baldiotti E, Ruzzenente A, Iacono C, et al. Elevated fibrinogen plasma level is not an independent predictor of poor prognosis in a large cohort of Western patients undergoing surgery for colorectal cancer. World J Gastroenterol. 2016;22:9994–10001.CrossRef
32.
33.
Toiyama Y, Inoue Y, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, et al. Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg. 2015;100:199–207.CrossRef
34.
Leitch EF, Chakrabarti M, Crozier JEM, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266–70.CrossRef
35.
Lee YS, Suh KW, Oh SY. Preoperative thrombocytosis predicts prognosis in stage II colorectal cancer patients. Ann Surg Treat Res. 2016;90:322–7.CrossRef
36.
Kulik U, Schrem H, Bektas H, Klempnauer J, Lehner F. Prognostic relevance of hematological profile before resection for colorectal liver metastases. J Surg Res. 2016;206:498–506.CrossRef
37.
Nyasavajjala SM, Runau F, Datta S, Annette H, Shaw AG, Lund JN. Is there a role for pre-operative thrombocytosis in the management of colorectal cancer? Int J Surg. 2010;8:436–8.CrossRef
38.
Rao X-D, Zhang H, Xu Z-S, Cheng H, Shen W, Wang X-P. Poor prognostic role of the pretreatment platelet counts in colorectal cancer. Medicine. 2018;97:e10831.CrossRef
39.
Del Prete M, Giampieri R, Loupakis F, Prochilo T, Salvatore L, Faloppi L, et al. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget. 2015;6:33982–92.PubMedPubMedCentral
40.
41.
42.
Neal CP, Mann CD, Sutton CD, Garcea G, Ong SL, Steward WP, et al. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer. 2009;45:56–64.CrossRef
43.
44.
Pawlik TM, Vauthey J-N. Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome. Ann Surg Oncol. 2008;15:677–9.CrossRef
Metadata
Title
Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases
Authors
C. Pedrazzani
G. Turri
G. Mantovani
C. Conti
R. Ziello
S. Conci
T. Campagnaro
A. Ruzzenente
A. Guglielmi
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02093-z

Other articles of this Issue 12/2019

Clinical and Translational Oncology 12/2019 Go to the issue

Brief Research Article

Neuroblastoma: validation of the INRG classification system in a small series

Research Article

Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?

Research Article

Socio-economic impact on women diagnosed and treated for breast cancer: a cross-sectional study

Brief Research Article

Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status

Review Article

miRNA signatures in childhood sarcomas and their clinical implications

Research Article

Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits